ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Viking Therapeutics Inc

Viking Therapeutics Inc (VKTX)

59.38
2.20
(3.85%)
At close: July 15 4:00PM
59.3224
-0.0576
( -0.10% )
After Hours: 4:40PM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
59.3224
Bid
59.30
Ask
59.65
Volume
2,105,505
56.66 Day's Range 60.00
8.28 52 Week Range 99.3999
Market Cap
Previous Close
57.18
Open
57.63
Last Trade
4
@
59.64
Last Trade Time
16:45:24
Financial Volume
$ 123,238,099
VWAP
58.5314
Average Volume (3m)
3,497,350
Shares Outstanding
110,268,210
Dividend Yield
-
PE Ratio
-76.23
Earnings Per Share (EPS)
-0.78
Revenue
-
Net Profit
-85.9M

About Viking Therapeutics Inc

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, ti... Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Viking Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker VKTX. The last closing price for Viking Therapeutics was $57.18. Over the last year, Viking Therapeutics shares have traded in a share price range of $ 8.28 to $ 99.3999.

Viking Therapeutics currently has 110,268,210 shares outstanding. The market capitalization of Viking Therapeutics is $6.31 billion. Viking Therapeutics has a price to earnings ratio (PE ratio) of -76.23.

Viking Therapeutics (VKTX) Options Flow Summary

Overall Flow

Bearish

Net Premium

-17k

Calls / Puts

140.00%

Buys / Sells

70.00%

OTM / ITM

414.29%

Sweeps Ratio

0.06%

VKTX Latest News

Viking Therapeutics Presents Preclinical Data on Novel Dual Amylin and Calcitonin Receptor Agonists at 84th Scientific Sessions of the American Diabetes Association

Viking Therapeutics Presents Preclinical Data on Novel Dual Amylin and Calcitonin Receptor Agonists at 84th Scientific Sessions of the American Diabetes Association PR Newswire SAN DIEGO, June...

Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)

Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) PR Newswire SAN DIEGO...

Viking Therapeutics to Participate at Upcoming Investor Conferences

Viking Therapeutics to Participate at Upcoming Investor Conferences PR Newswire SAN DIEGO, May 30, 2024 SAN DIEGO, May 30, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:...

Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update PR Newswire SAN DIEGO, April 24, 2024 Conference call scheduled for 4:30 p.m. ET today Results From...

U.S. Futures Display Mixed Results Amid Earnings, WTI and Brent Crude Prices Dip in June Futures Trading

U.S. index futures are showing mixed results in pre-market trading this Wednesday, as investors assess the latest financial results released. As of 6:31 AM, Dow Jones Industrial Average futures...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
17.572414.632657004851.7560.2350.1711277915256.48495491CS
47.922415.41322957251.460.2346.11401204452.63293752CS
12-4.6376-7.2507817385963.9681.8646.11349735061.25200993CS
2638.0924179.42722562421.2399.399920.28494065365.10848741CS
5243.8424283.21963824315.4899.39998.28356330049.3074599CS
15653.4724914.0581196585.8599.39992.02242923029.55940756CS
26051.0324615.589867318.2999.39992.02196804223.42299684CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
WNWMeiwu Technology Company Ltd
$ 1.38
(55.06%)
2.97M
SVRESaverOne 2014 Ltd
$ 0.53
(19.34%)
2.85M
ETONEton Pharmaceuticals Inc
$ 3.65
(9.28%)
212.27k
AZA2Z Smart Technologies Corporation
$ 0.8632
(9.27%)
945
VIRXViracta Therapeutics Inc
$ 0.58
(9.23%)
200
CYNCYNGN Inc
$ 8.12
(-11.55%)
113.07k
AMIXAutonomix Medical Inc
$ 1.24
(-10.14%)
773.84k
KTTAPasithea Therapeutics Corporation
$ 5.51
(-9.08%)
1.84k
QLGNQualigen Therapeutics Inc
$ 0.355
(-8.20%)
307.21k
DMACDiaMedica Therapeutics Inc
$ 3.2995
(-7.84%)
171
FFIEFaraday Future Intelligent Electric Inc
$ 0.547
(6.17%)
5.35M
TSLATesla Inc
$ 253.02
(0.15%)
4.09M
AAPLApple Inc
$ 234.8399
(0.19%)
3.88M
WNWMeiwu Technology Company Ltd
$ 1.38
(55.06%)
2.97M
MAXNMaxeon Solar Technologies Ltd
$ 0.2238
(-1.41%)
2.89M

VKTX Discussion

View Posts
TechandBio TechandBio 7 days ago
In since $3.50 sold initial investment at 87.00 riding the houses $

$VKTX
👍️0
Monksdream Monksdream 3 months ago
VKTX 10Q due 4/24
Next day settlement begins 5/28

👍️0
Jimmy Swaggert Jimmy Swaggert 3 months ago
I bet an ELI or NOVO buyout is soon.
👍️0
Monksdream Monksdream 4 months ago
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?orderBy=percentChange&orderDir=desc
👍️0
Awl416 Awl416 4 months ago
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
👍️ 1
budgetthis budgetthis 4 months ago
What a crazy couple of weeks……

Time to jump back in from these levels ??

I think so.

$$ VKTX $$

👍️0
TheFinalCD TheFinalCD 4 months ago
$VKTX $70'S FROM 79
👍️0
TheFinalCD TheFinalCD 4 months ago
$vktx $VKTX Truist PT 120

Raymond James PT 115

Irrational selloff

Recall $MDGL irrational selloff I was beating the drum when shares dropped to $168 or so after early data $LLY reported data for MASH

In just few weeks $MDGL actually went higher from selloff pivot point

A $100+…— Pharmdca (@Pharmdca) March 8, 2024
👍️0
budgetthis budgetthis 4 months ago
Another marvelous day, fellow Vikings.

Let’s get over $100 already, lol.

$$ VKTX $$
👍️0
north40000 north40000 4 months ago
It doesn’t have to own a plant, but it does need a plant that will make its pipeline of molecules better than the Indiana plant of CTLT (NOVO NORDISK) that just got slapped with a warning letter from FDA. I suggested CDMO whose reactor plants have always been FDA approved for good manufacturing methods. Avid Bioservices (CDMO) has supplied raw material to HALO for years to make its Enhanze delivery system for molecules e.g., JNJ’s Darzalex.
👍️0
DewDiligence DewDiligence 4 months ago
Why does VKTX need a proprietary delivery system?
👍️0
north40000 north40000 4 months ago
Are you aware of LEXX? Said to have a delivery system for molecules like VKTX has that will turn both into a blockbuster.

I understand that VKTX has no facilities with reactors capable of making its pipeline of molecules. CDMO has an expanded capacity plant up the coast from San Diego in Tustin, and a wholly new plant further up the coast near John Wayne airport. GILD has plants in Forest City, and JNJ has plants in South San Francisco. What do you hear on the topic?
👍️0
budgetthis budgetthis 5 months ago
Buying opportunity, imho……

$80 call options look really good to me at this time, imho.

Go Viking!
👍️0
DewDiligence DewDiligence 5 months ago
VKTX sells—(upsized)—7.44M* shares@ $85.00—essentially_no_discount_to_Tuesday’s_closing_price:

https://www.prnewswire.com/news-releases/viking-therapeutics-announces-pricing-of-550-million-public-offering-of-common-stock-302074989.html

Net proceeds will be ~$595M* after underwriting fees.

*Assuming exercising of underwriter’s option.
👍️ 1
budgetthis budgetthis 5 months ago
Another great day…….lets bust through $100 this week.

Oppenheimer adjusts their VKTX price target to $116…….maintains outperform rating.

$$ VKTX $$
👍️0
JasonT1 JasonT1 5 months ago
If I had this stock at .08, I would be selling.
👍️0
JasonT1 JasonT1 5 months ago
Didn't ask for much money. This stock will continue to rise.
👍️0
DewDiligence DewDiligence 5 months ago
$1,260,000,000 billion in debt.You need a better pair of glasses—this is VKTX’s 12/31/23 balance sheet:

https://www.sec.gov/ixviewer/ix.html?doc=/Archives/edgar/data/0001607678/000095017024012322/vktx-20231231.htm#balance_sheets
👍️ 1
north40000 north40000 5 months ago
GILD is providing at least $12 miliion in grant money over 3 years to scores of institutions, states and cities scattered around the country to help women and transgenders to combat HIV. Will this program make Biktarvy available, or will it make VKTX oral/injectable med available, or both. The bigger question is whether GILD will use its remaining cash $$$ to acquire/merge with VKTX, IMO.
👍️0
TheFinalCD TheFinalCD 5 months ago
Viking Therapeutics proposes $350M stock offering after shares more than double in value

https://www.msn.com/en-us/money/markets/viking-therapeutics-proposes-350m-stock-offering-after-shares-more-than-double-in-value/ar-BB1j0cVc#:~:text=Viking%20Therapeutics%20%28NASDAQ%3AVKTX%29%20on%20Tuesday%20announced%20a%20proposed,trading%20following%20positive%20results%20from%20a%20mid-stage%20trial.
👍️ 1
Sir Duke Wonder Sir Duke Wonder 5 months ago
Your debt number is high by a factor of 1,000 and they have hundreds of millions in cash enough for a dozen quarters. And the new offering will double that cash and give them enough cash to make it to market, if they choose.
👍️0
Tim696969 Tim696969 5 months ago
It's 1.26 million, not billion in debt.
👍️0
Invest-in-America Invest-in-America 5 months ago
VKTX: And the REAL REASON for this unusual run-up!!! (Brilliantly articulated in the below article!!!)

"MW Viking Therapeutics stock almost doubles as investors cheer cheap entry to weight-loss-drug craze"
https://www.marketwatch.com/story/viking-therapeutics-stock-soars-61-premarket-after-company-reports-positive-results-in-trial-of-weight-loss-drug-50e81767

(I.e., who would have thought that the already 'high' price of VKTX would be viewed as "CHEAP"?? But it indeed is shockingly CHEAP, when compared to the only other two significant PLAYERS in entire 'Weight Loss' science field!!)
👍️0
vinmantoo vinmantoo 5 months ago
It's up 800% in 3 months this is not sustainable. Will blow threw current Cash in like a quarter and is already $1,260,000,000 billion in debt.

Are you new to biotech? VKTX will announce a stock offering in very short order, a day or two, certainly less than a week. It might be 10-15 million at $75/share for $750 million to $1.3 billion in cash so cash flow won't be an issue.
👍️0
make it happen make it happen 5 months ago
Better gain percent wise in 6 years than Apple, Nvidia, and many more in there entire life.

This was $0.08 cents now $70.00.....
👍️ 1
make it happen make it happen 5 months ago
This has done a bigger percent gain overall than Apple and every company I can think of in the market in a couple years. This is not sustainable in the least bit. Imho
👍️0
make it happen make it happen 5 months ago
A fade to 50 is still up 500% in 3 months
👍️0
make it happen make it happen 5 months ago
It's up 800% in 3 months this is not sustainable. Will blow threw current Cash in like a quarter and is already $1,260,000,000 billion in debt.

With a book value of $3 and change
👍️0
make it happen make it happen 5 months ago
$VKTX Debt $1,260,000,000 billion

Cash Flow Statement
Operating Cash Flow $-73.38M
Levered Free Cash Flow $-42.36M

Huge negatives

Management Effectiveness
Return on Assets -23.47%
Return on Equity -34.79%

Negative returns in large double digits

Book Value Per Share $3.48
1/20 current share price

Profitability
Profit Margin 0.00%
Operating Margin 0.00

Zero profitability
👍️0
TheFinalCD TheFinalCD 5 months ago
I did a small test short @ 80.47 it dropped to 66 after

WOW should have loaded the tub
👍️0
TheFinalCD TheFinalCD 5 months ago
Had a position since I was in my teens
👍️0
Monksdream Monksdream 5 months ago
Had a position since the teens
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
February 27 2024 - 07:03AM
PR Newswire (US)
Alert
Print
Share On Facebook
Study Achieves Primary and all Secondary Endpoints, Demonstrating Statistically Significant Reductions in Body Weight at all Doses as Compared to Placebo

Up to 13.1% Placebo-Adjusted Mean Weight Loss (14.7% From Baseline) Observed After 13 Weeks of Treatment; No Plateau Observed

VK2735 Shown to be Safe and Well-Tolerated in 13-Week Study; 95% of GI-specific Treatment Emergent Adverse Events Considered Mild or Moderate

Conference Call Scheduled for 8:00 a.m. ET Today

SAN DIEGO, Feb. 27, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced positive top-line results from the company's Phase 2 clinical trial of VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors in development for the potential treatment of various metabolic disorders such as obesity. The Phase 2 VENTURE trial successfully achieved its primary endpoint and all secondary endpoints, with patients receiving VK2735 demonstrating statistically significant reductions in body weight compared with placebo. Additionally, the study showed VK2735 treatment to be safe and well tolerated with the majority of treatment emergent adverse events (TEAEs) being categorized as mild or moderate. Based on these findings, Viking intends to meet with the FDA and discuss next steps in the development of VK2735.
👍️0
TheFinalCD TheFinalCD 5 months ago
HUGE day

$VKTX
👍️0
Awl416 Awl416 5 months ago
Hell of an investment

Congrats
👍️ 1
TheFinalCD TheFinalCD 5 months ago
WOW $26-$36 quick
👍️0
TheFinalCD TheFinalCD 5 months ago
Viking Therapeutics gains amid renewed takeover speculation

12:34 PM | Viking Therapeutics, Inc. (VKTX) | By: SA Editor Joshua Fineman, SA News Editor
👍️0
Monksdream Monksdream 5 months ago
VKTX new 52 week high
👍️0
DewDiligence DewDiligence 5 months ago
I'll take the other side of that bet, LOL.
👍️0
Biggeoff Biggeoff 5 months ago
Buyout coming this week. Might halt pre market Monday and announce it
👍️0
Monksdream Monksdream 5 months ago
VKTX new 52 week high
👍️0
MWM MWM 5 months ago
Monster in the making here $VKTX

Next up, Viking expects to have the results of two studies for its drug, dubbed VK2735. One will test the under-the-skin shot over 13 weeks as an obesity treatment. The other will study the oral pill over 28 days in otherwise healthy adults with obesity.

https://www.investors.com/news/technology/vktx-stock-charges-to-a-record-high-on-an-update-for-its-lilly-rivaling-obesity-treatment/
👍️0
Monksdream Monksdream 5 months ago
VKTX new 52 week high
👍️0
Whalatane Whalatane 6 months ago
Jan 2 opinion from Larry Ramer
Viking Therapeutics (NASDAQ:VKTX) owns a potential weight-loss, cholesterol, and liver-disease treatment called VK2735. In a Phase 1 trial of the drug, the liver fat of patients taking VK2735 fell “up to 47.2%.” Moreover, the cholesterol levels of the four patients taking the highest dose of the drug dropped by an average of 21%.

Also noteworthy is that the drug was found to be “well-tolerated.”

Last month, Barron’s stated that ” Pfizer could look to make a deal with a biotech developing an anti-obesity pill, given the roadblocks its own internally-developed anti-obesity pill has hit. ”

Given the fact that weight-loss drugs are expected to be very lucrative, while Viking’s VK2735 performed quite well in its Phase I trial, I believe that Viking could easily be acquired by Pfizer (NYSE:PFE) or another large company that does not have its own highly effective obesity treatment.
--------------
Kiwi
👍️0
Biorat Biorat 9 months ago
VKTX investors look at the similarities

Whether It’s Cloudy Or Sunny, You Should Be Buying Context Therapeutics (CNTX)

(Take a look at CONTEXT Therapeutics) CLDN6 is in development by Context Therapeutics (CNTX) and is designed to be activated only upon tumor engagement while silent elsewhere. This allows CLDN6 to redirect T-cell activation away from where it would be harmful and enhances the safety profile vs its peers and what they are developing. There is an immense market given the absolute need for a high specificity to solid tumor cell treatment. $6-$15 a share is reasonable within 12 months given the upcoming Society for Immunotherapy of Cancer meeting could alert investors to a potential blockbuster. CNTX shares could easily climb multiples times higher given the tightly held float. By the time investors realize claudin 6 is an exceptionally attractive investment CNTX shares will likely be trading over $4 a share and heading higher. At the point clinical trails start showing their results be prepared to pony up for shares. There is opportunity to get in before the bulk of investors learn the potential market value of a pending CLND6 blockbuster. There are also other irons in the fire at Context Therapeutics to maintain share holder excitement as well. Stay tuned for updates on the pipeline as fact checking is near completion. CNTX stock has been beaten down just like the shares of Viking Therapeutics (VKTX) had been before running up to over $25 a share.

Right now the shares of CNTX are held tight and likely have only a small pool available. The 12-month stock price forecast for CNTX stock is $4.00, which predicts an increase of 164.90%. On average, analysts rate CNTX stock as a buy. There is a growing consensus among some investors that forecast is far to conservative with a $6.25-$15 range seeming a more realistic target within a year. Do some homework and see the opportunity before the masses. Things tend to get heated early with real potential like this. Don't believe it? Look over Viking Therapeutics (VKTX) where it traded under $2 a share. CNTX isn't different it's poised for the same type of breakout. Look at the 5 year chart and your eye will be open.

Investors should not forget Context Therapeutics announced on December 6, 2021 it had closed a previously announced placement of 5 million shares at a price of $6.25 per share.  ThinkEquity acted as the sole placement agent and had no problem finding placement of those shares. There's a reason for that and that reason has not changed. The beat down of the share price is now over and referring back to  Viking Therapeutics it had the same beat down before running up to over $25 a share.  In fact on September 16, 2018 VKTX shares traded at $18.20 at the close of the day before being beaten down to $2.23 a share on June 5, 2022 only to breakout and run to $24.27 on June 4, 2023.  Even before that on July 30, 2017 VKTX shares closed at a mere 98 cents. There is a way to invest and that's been proven over and over. Get in early after the beat down is over if the facts on the ground have not changed.

Due your own research and the wise will should agree. 
👍️0
Biorat Biorat 9 months ago
(Take a look at CNTX) CLDN6 is in development by Context Therapeutics (CNTX) and is designed to be activated only upon tumor engagement while silent elsewhere. This allows CLDN6 to redirect T-cell activation away from where it given the upcoming Society for Immunotherapy of Cancer meeting will alert investors to the potential. CNTX shares could easily climb multiples times higher given the tightly held float. By the time investors realize claudin 6 is an exceptionally attractive investment CNTX shares will likely be trading over $4 a share and heading higher. At the point clinical trails start showing results be prepared to pony up for shares. There is opportunity to get in before the bulk of investors learn the market value of a pending CLND6 blockbuster. There are other irons in the fire at Context Therapeutics for share holder excitement as well. Stay tuned for updates on the pipeline as fact checking is near completion. CNTX stock had been beaten down just like the shares of Viking Therapeutics(VKTX) Had been before running up to over $25 a share.

Right now the shares of CNTX are held tight and only have a small pool available. The 12-month stock price forecast for CNTX stock is $4.00, which predicts an increase of 164.90%. On average, analysts rate CNTX stock stock as a buy. There is a growing consensus that forecast is far to conservative. $6-$15 seems a more realistic target within a year. Do some homework and see the opportunity before the masses. Things tend to get heated early with real potential like this.... Don't believe it? Look over VKTX where it traded under $2 a share. CNTX isn't different it's poised for the same type of breakout. Look at the 5 year chart and your eye will be open.would be harmful and enhances the safety profile vs its peers and what they are developing. There is an immense market given the absolute need for a high specificity to solid tumor cell treatment. $6-$15 a share is reasonable within 12 months
👍️0
Biorat Biorat 10 months ago
I don't like the way VKTX is trading. Looking at CNTX instead looks like VKTX before the run up. Lower shares than VKTX and ground floor anything under $4 so we are talking really good returns on the upcoming events.
👍️0
Biorat Biorat 10 months ago
OVERALL FLOW - Bearish for Viking Therapeutics Inc. Up on low volume after a new low in the morning. Did not test the real support today before being manipulated up on low volume. Look for down days ahead. Not worth chasing with an overall bearish indication. The bottom must be tested first.
52 week range $2.59 - $25.7199..... No entry till we test $10.51 and it's not been tested. If VKTX breaks lower it might drop and test the $9's. Todays range at this time $10.67 - $11.31

No way the low does not get tested in the next trading session or next week.
👍️0
DewDiligence DewDiligence 12 months ago
New $200M ATM with Stifel et al:

https://www.sec.gov/Archives/edgar/data/1607678/000095017023034818/form_s-3_asr_2023.htm (scan past the shelf registration to separate section of filing regarding the ATM)
👍️0
DewDiligence DewDiligence 12 months ago
Brief notes on VK2735 oral formulation from today’s 2Q23 CC:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172444594
👍️0
tootalljones tootalljones 1 year ago
I think we are at the apex of this bull market, the very top, and it is all down hill from here, Nobody escapes alive. and that the reason for this decline in viking and MDGL is somewhat related to Pfizer announcement...............but that is just one cause. I am expected virtually all stocks to go down. sorry, my 2 cents.
👍️ 1

Your Recent History

Delayed Upgrade Clock